From a perspective of health - care system in China, the current model predicted that camrelizumab-chemotherapy combination therapeutic regime would offer obviously marked benefits to patients of IIIB–IV non-sq NSCLC without EGFR and ALK alteration in comparison with chemotherapy alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.